It's a very good question, Mr. Davies. My answer, just very briefly, as certainly I am no expert in national pharmacare in all its various dimensions, is that I do believe the model we operate is worthy of extensive analysis and research. I believe it is replicable in some ways for certain classes of drugs. It is not the panacea to every issue that a national pharmacare program needs to grapple with, and it's not just about bulk purchasing and price benefits. It's really those other dimensions that I spoke to: ensuring security of supply and patient choice and physician input, and equitable access right across the country.
I think there are several dimensions. We're simply offering our model, open to all those interested, for worthy analysis. I do believe components of it are relevant for some of the debates around national pharmacare.